NEW DELHI — A pending Supreme Court patent decision in India could reverberate throughout the pharmaceutical industry and beyond.
India's Supreme Court is to rule Monday on a landmark patent case involving Swiss drugmaker Novartis AG.
The international drug makers have been pushing for stronger patent protection in India to regulate the country's $26 billion generic drug industry, which they say often flouts intellectual property rights. They warn that a rejection of Novartis' position could discourage new research and refinement.
At issue is a legal provision in India's 2005 patent law aimed at preventing companies from getting fresh patents for minor changes to medicines — a practice known as "evergreening."
The drug in question is called Gleevec and it's used to treat leukemia and other cancers. It costs $2,600 a month while the generic version available in India costs around $175 per month.
Anda sedang membaca artikel tentang
India's top court to deliver Novartis judgment
Dengan url
http://sedangapasaja.blogspot.com/2013/03/india-top-court-to-deliver-novartis.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
India's top court to deliver Novartis judgment
namun jangan lupa untuk meletakkan link
India's top court to deliver Novartis judgment
sebagai sumbernya
0 komentar:
Posting Komentar